Therefore, the combination of trastuzumab and fulvestrant, which had positive synergistic effects in our experiments, may constitute an improved course of treatment for HR+/HER2+ advanced breast cancer resistant to previous hormone therapies. The gene discussed is ERBB2; the disease is breast cancer.